DekaBank Deutsche Girozentrale Buys 37,544 Shares of Zoetis Inc. (NYSE:ZTS)

DekaBank Deutsche Girozentrale raised its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 11.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 370,422 shares of the company's stock after buying an additional 37,544 shares during the period. DekaBank Deutsche Girozentrale owned 0.08% of Zoetis worth $60,174,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of Zoetis by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock worth $6,739,905,000 after buying an additional 120,158 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Zoetis by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company's stock valued at $1,726,075,000 after buying an additional 190,137 shares during the period. Polen Capital Management LLC lifted its holdings in Zoetis by 17.5% during the fourth quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company's stock valued at $1,219,237,000 after purchasing an additional 1,116,541 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Zoetis by 78.5% in the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock worth $1,133,755,000 after buying an additional 3,059,255 shares during the period. Finally, Northern Trust Corp grew its position in shares of Zoetis by 13.3% in the fourth quarter. Northern Trust Corp now owns 6,426,394 shares of the company's stock valued at $1,047,052,000 after purchasing an additional 755,893 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the transaction, the executive vice president directly owned 15,129 shares of the company's stock, valued at approximately $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Zoetis Price Performance

Shares of Zoetis stock opened at $157.72 on Wednesday. The firm has a market capitalization of $70.22 billion, a PE ratio of 28.32, a price-to-earnings-growth ratio of 2.60 and a beta of 0.91. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The business's 50-day moving average price is $161.27 and its 200-day moving average price is $161.99.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The firm's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.38 earnings per share. Sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a yield of 1.27%. Zoetis's payout ratio is currently 35.91%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ZTS. UBS Group decreased their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and lowered their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, Piper Sandler lifted their price target on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Monday, May 12th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Zoetis has an average rating of "Buy" and an average price target of $212.13.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.